相关论文

Abstract:BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin-angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P = 0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P = 0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P = 0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years. (Funded by Janssen Research and Development; CREDENCE ClinicalTrials.gov number, NCT02065791.).

参考文献

[1]  G. Bakris,et al.  Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis , 2019, Current Hypertension Reports.

[2]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[3]  B. Joe,et al.  Salt-Responsive Metabolite, β-Hydroxybutyrate, Attenuates Hypertension , 2018, Cell reports.

[4]  K. Mahaffey,et al.  Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. , 2018, The lancet. Diabetes & endocrinology.

[5]  M. M. Joosten,et al.  Magnesium and Blood Pressure: A Physiology-Based Approach. , 2018, Advances in chronic kidney disease.

[6]  A. Vaag,et al.  MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism? , 2018, European journal of endocrinology.

[7]  B. Zinman,et al.  Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial , 2017, Diabetes Care.

[8]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[9]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[10]  B. Zinman,et al.  Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial , 2016, European heart journal.

[11]  Amit X Garg,et al.  Worldwide access to treatment for end-stage kidney disease: a systematic review , 2015, The Lancet.

[12]  U. Broedl,et al.  Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.

[13]  G. Guyatt,et al.  Problems of stopping trials early , 2012, BMJ : British Medical Journal.

[14]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[15]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[16]  B. Brenner,et al.  Diverse biological actions of atrial natriuretic peptide. , 1990, Physiological reviews.

[17]  B. Brenner,et al.  Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration. , 1987, The Journal of clinical investigation.

引用
Chronic kidney disease: summary of updated NICE guidance
BMJ
2021
Beta-blockers in heart failure patients with severe chronic kidney disease-time for a randomized controlled trial?
Nephrology, Dialysis and Transplantation
2019
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
Circulation
2020
Use of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry
European journal of heart failure
2021
Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study
Journal of diabetes investigation
2020
SGLT-2 inhibitors in diabetes: a focus on renoprotection.
Revista da Associacao Medica Brasileira
2020
Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases
European journal of preventive cardiology
2019
Non‐insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials
ESC heart failure
2020
CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS.
Cardiovascular research
2021
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure
European journal of heart failure
2019
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
Reviews in cardiovascular medicine
2022
Review of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy
Therapeutic advances in endocrinology and metabolism
2019
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial.
Circulation
2019
The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial
Diabetes, obesity & metabolism
2020
Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial
Diabetes, obesity & metabolism
2020
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
Diabetes, obesity & metabolism
2021
Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes, obesity & metabolism
2021
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA‐REG OUTCOME trial
Diabetes, obesity & metabolism
2020
Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon‐like peptide‐1 receptor agonists or sodium‐glucose cotransporter‐2 inhibitors: A real‐world study in two Italian cohorts
Diabetes, obesity & metabolism
2021
Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial
Diabetes, obesity & metabolism
2021